Poor
Needs Revision
Patient Risk:
High
Summary
Several safety/usage claims are not supported by the provided label excerpts, and one claim directly contradicts the boxed warning/label limitation (not approved for dementia-related psychosis). Most other statements are generic or mechanism/side-effect claims that are not verifiable against the supplied label text.
Category Scores
Accurate Statements
Latuda is not approved for the treatment of patients with dementia-related psychosis.
Boxed Warning: “LATUDA is not approved for the treatment of patients with dementia-related psychosis…”
Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death.
Boxed Warning/5.1: “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults, and patients should be monitored for clinical worsening and emergence of suicidal thoughts/behaviors.
Boxed Warning/5.2: “Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults…” and “Closely monitor all antidepressant-treated patients…”
Unsupported Statements
Latuda is a prescription brand-name antipsychotic.
The provided label excerpts do not state “prescription brand-name” or “antipsychotic” in a way that can be verified against the supplied text.
Latuda contains lurasidone.
The provided label excerpt text shown does not explicitly link LATUDA with “contains lurasidone” (though it refers to lurasidone in headings/sections); direct statement support is not present in the provided excerpts.
Latuda is used to treat schizophrenia.
Supported by Indications section, but the excerpts provided for indications do support schizophrenia—however this claim is generic to adults/adolescents and the provided evidence is partial to not specify adult/adolescent scope in the statement; treated as unsupported in strict matching to the user’s simplified phrasing.
Latuda is used to treat bipolar depression.
Supported by Indications section, but the statement does not specify monotherapy vs adjunct and age limitations; strict match to excerpt details is not provided.
Latuda's effects come from how it changes signaling in the brain.
Mechanism-of-action phrasing is not present in the provided excerpts.
Lurasidone is designed to act on key dopamine receptors and serotonin receptors.
Receptor targets are not present in the provided excerpts.
Lurasidone helps with symptoms related to psychosis and mood disorders.
Efficacy language about symptom targets is not present in the provided excerpts.
Common side effects of Latuda can include somnolence (sleepiness).
Adverse reaction examples are not provided in the supplied label excerpts.
Common side effects of Latuda can include nausea.
Adverse reaction examples are not provided in the supplied label excerpts.
Common side effects of Latuda can include restlessness.
Adverse reaction examples are not provided in the supplied label excerpts.
Common side effects of Latuda can include movement-related effects.
Adverse reaction examples are not provided in the supplied label excerpts.
Patients taking Latuda can be affected by metabolic changes depending on the individual and the specific medication regimen.
Metabolic changes/adverse metabolic effects are not present in the supplied excerpts.
Latuda dosing depends on the specific condition being treated and a person's age and overall health.
Dosing detail language beyond the existence of dosage sections is not present in the supplied excerpts.
Taking Latuda consistently as prescribed matters.
Adherence counseling language is not present in the supplied excerpts.
Missed doses of Latuda should be handled according to the prescriber's instructions or the medication label.
Missed-dose instructions are not present in the supplied excerpts.
Generic versions of Latuda may depend on patent status and approvals for lurasidone.
Regulatory/patent statements are not present in the supplied label excerpts.
Antipsychotics can interact with other medicines.
The provided excerpts include CYP3A4 inhibitor/inducer contraindications but do not support a general statement about interactions without specifics.
Antipsychotics can have risks related to sedation.
Sedation risk is not present in the supplied excerpts.
Antipsychotics can have risks related to movement disorders.
Movement-disorder risk is not present in the supplied excerpts.
Antipsychotics can have risks related to metabolic changes.
Metabolic risk is not present in the supplied excerpts.
Patients should review the full medication list (including over-the-counter drugs and supplements) with a clinician or pharmacist.
This counseling instruction is not present in the supplied excerpts.
Contradictions
High
AI Statement
LATUDA is approved for the treatment of dementia-related psychosis.
Label Reference
Boxed Warning: “LATUDA is not approved for the treatment of patients with dementia-related psychosis…”
Important Omissions
For the boxed warning/suicidality content, the response did not clearly and explicitly state the label’s specific limitation (“not approved for dementia-related psychosis”) and the antidepressant attribution/monitoring language as written (instead it provided only generic interaction/sedation/movement/metabolic themes).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
A contradictory claim exists regarding approval for dementia-related psychosis, which is specifically addressed by the boxed warning/label limitation. Multiple additional safety-related statements (side effects, sedation, movement/metabolic risks, interactions) are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
At least one claim contradicts the boxed warning/label limitation about dementia-related psychosis approval; many other claims are generic and not supported by the supplied label text.
Suggested Improvement
Restrict claims to the provided label excerpts (e.g., Indications/Usage and the boxed warning statements). Remove or rephrase unsupported generic statements (mechanism, receptor targets, specific common side effects, sedation/movement/metabolic risks, interaction counseling) unless the matching label text is supplied. Ensure the dementia-related psychosis approval limitation is stated correctly as “not approved.”